THANK YOU FOR SUBSCRIBING
Pharma Tech Outlook | Friday, October 29, 2021
Pharmaceutical businesses' rising pressure to improve their return on investment will fuel the pharma outsourcing industry.
FREMONT, CA: The healthcare industry has undergone dramatic transformations in recent years. The growing importance of contract research organizations (CROs) and contract manufacturing organizations (CMOs), the rapid adoption of innovative technologies such as automation and artificial intelligence, and the growing pressure on governments worldwide to reduce the healthcare burden were just a few of the themes that influenced the pharmaceutical industry over the years.
Stay ahead of the industry with exclusive feature stories on the top companies, expert insights and the latest news delivered straight to your inbox. Subscribe today.
For an extended period, the industry's most serious challenges have been the significant R&D expenditure and falling return on investment. Combine this with regulatory and political pressure on medicine pricing and the need to increase productivity and efficiency across the value chain. Outsourcing has long been a popular method for pharmaceutical businesses to increase operational efficiencies, geographical reach, therapeutic expertise, and on-demand services.
Additional Consolidation
The pharmaceutical outsourcing market is fragmented, with many firms offering both end-to-end and specialty services. On the other hand, the larger outsourcing organizations aim to acquire specialty / high-impact service or manufacturing businesses to bolster their existing capabilities.
A shift in Outsourcing Motivations
Outsourcing enables businesses to save money on resources, infrastructure, and other overhead costs. Although cost savings remain the primary rationale for numerous outsourcing tasks across the sector, there has been a sea change in the outsourcing motivations of several large pharma corporations. Pharmaceutical companies cite increased quality and decreased time-to-market in today’s market as primary reasons for outsourcing their business tasks to CROs, CDMOs, and contract sales organizations (CSOs).
With market consolidation (a sign of maturity), these outsourcing firms will compete to become strategic partners of pharmaceutical corporations rather than simply remaining a service/commodity provider.
Additional Bundled Deals
Bundling services is supposed to increase outsourcing's efficiency by delivering end-to-end solutions. This will save pharmaceutical businesses money and provide them with increased control, visibility, and flexibility. In the R&D arena, the industry anticipated packaged solutions for trial planning, conduct, and reporting.
Increased Service Offerings
Pharmaceutical businesses are increasingly outsourcing operations to cut costs. Formulation development, analytical and testing services, API production, clinical trial management, and solid dose manufacturing are just a few services that benefit pharmaceutical companies.
More in News